Medsaf

Medsaf


Medsaf (www.Medsaf.com), Africa’s premier pharmaceutical technology provider of genuine and authentic medications today announced the strengthening of its management team with three new appointments. Mr. Joao Pinheiro, Mr. Obinna Ajeroh and Mr. Kenny Oriola have respectively been named as Chief Technology Officer, Business Development Director and Head of Operations of Medsaf. All three newly appointed executives will join Medsaf with immediate effect.

Through proprietary technology, data analytics and quality control, Medsaf combats the proliferation of fake medicines by increasing access, affordability and quality of medications dispensed to Africans. In pursuit of this strategy, Medsaf has seen tremendous growth since it launched in 2017, experiencing an average yearly growth rate of 150%, growing over 500% in 2021 alone. The company has raised US$2.7 million since inception from investors such as Lateral Capital, Samurai Incubate, Seedstars, Musha Ventures, Spark, Yvonne Wassenaar, Proparco, and Stonks. With regional growth plans to expand beyond Nigeria into Kenya and West Africa, Medsaf currently offers a range of products and services designed to improve patient care.

Aligned with its ambitious growth and expansion plan for 2022, Medsaf is strengthening the management team by expanding the company’s executive capabilities.

Speaking to the new appointments, Vivian Nwakah, Co-founder&Chief Executive Officer of Medsaf said: “Medsaf has positioned itself as a solution-provider to one of the most challenging issues in the healthcare space in Africa, gaining access to genuine and authentic medication. We are of a new breed of startups, on the edge of fintech and healthtech.  Building on from the expansion we experienced in 2021, we plan to pursue even greater growth opportunities in 2022. Through increasing access for all Africans to affordable, quality medication, when and where they need them, Medsaf supports a fundamental human right by addressing a significant public health crisis. Mr Pinheiro, Mr. Ajeroh and Mr Oriola are eminently qualified to help Medsaf pursue growth opportunities and we look forward to their leadership and impact.”

Pinheiro has more than 25 years of experience building and managing tech projects, including his former role as Lead Developer for Rocket Internet where he worked on early iterations of Jumia Africa. As a co-founder, he is returning to Medsaf with his experience spanning across many industries including cybersecurity, marketplaces, and warehousing. 

Oriola joins Medsaf from Kong, Africa’s second largest e-commerce platform, where he was Vice President of Operations and E-commerce. During his tenure at Konga, Oriola responsibilities included managing over 300 staff nationwide and was integral to the company achieving over 52% growth in 2020 while reducing overall operating expenses.  Prior to Konga, Oriola was the Co-Managing Director at DealDey, an African start-up in the online retail sector that raised over USD five million during its launch phase.  After graduating with an MSc in Financial Management from Middlesex  University, Oriola started his career in the investment banking and oil and gas sectors in Nigeria.

Ajeroh is an innovative, resolute business director with multiple years of experience working with the public, private and development sectors across multi-functional teams and within global business units holding senior executive roles at the Clinton Health Access Initiative, the Malaria Consortium and Novartis.  Ajeroh, a pharmacist by training, is a skilled specialist at improving team efficiencies, optimizing marketing and sales strategies and managing complex business situations. 

Distributed by APO Group on behalf of Medsaf.

Media Contact
Gilles Ametepe
Djembe Consultants
T: +233 24 86 066 52
Egilles@djembeconsultants.com

About Medsaf:
Founded in 2017 by Vivian Nwakah, a graduate of the University of Illinois at Urbana-Champaign, Medsaf is Africa’s premier pharmaceutical technology provider that is increasing the quality and access of medication dispensed in Africa through innovative technology and financing facilities. Through a 7-layer quality control vetting process, Medsaf is the first to provide patients with precise prices on the medications they need immediately through a simple and easy process. With a team across the continent backed by international funders and donors, Medsaf is currently embarking on an ambitious growth trajectory to impact the public health sector in Africa.  For more information, visit Medaf’s website (www.Medsaf.com). 

Send us your press releases to pressrelease.zawya@refinitiv.com


© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.